Loading
Cancer, Lipids, and Metabolism / Eicosanoids and Hypertension Pharmacology / Cancer, Hypoxia, and Metabolism · Journal article
Acs Pharmacology & Translational Science · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study demonstrating that oral arachidonic acid accelerates and docosahexaenoic acid suppresses tumorigenesis in a MYCN-driven mouse model, with oxylipin profiling suggesting competing eicosanoid pathways as drivers. The findings are suggestive but derived from a single animal model without clinical validation; they raise the hypothesis that dietary fatty acid composition modulates tumor progression via oxylipin signaling, not a practice-changing or even confirmatory claim.
Preclinical controlled experiment in a syngeneic MYCN-driven mouse model. MYCN-driven syngeneic mouse model of pediatric neuroblastoma; setting and eligibility criteria not detailed.. Intervention: Ultrahigh-dose oral arachidonic acid (4.7 g/day human equivalent) or docosahexaenoic acid (24 g/day human equivalent). Compared with: Control diet (composition not specified).
Arachidonic acid (4.7 g/day human equivalent) produced 100% tumor incidence with 4-fold larger masses than controls Docosahexaenoic acid (24 g/day equivalent) caused complete regression in half of tumors and slowed growth to 22% of control size and 6% of arachidonic acid size Arachidonic acid elevated pro-tumorigenic eicosanoids (PGE2, TXB2, EETs) via COX/LOX/CYP450 pathways
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies a potential mechanistic pathway linking dietary lipid composition to neuroblastoma progression but does not yet support clinical use. The proposed ultrahigh-dose omega-3 intervention requires confirmation in human neuroblastoma patients before consideration as an adjunct therapy.
Mechanistic preclinical study in a syngeneic mouse model showing lipid-dependent tumor fate; no human data, no clinical outcomes, and the proposed dietary intervention mechanism requires confirmation in humans.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies a potential mechanistic pathway linking dietary lipid composition to neuroblastoma progression but does not yet support clinical use. The proposed ultrahigh-dose omega-3 intervention requires confirmation in human neuroblastoma patients before consideration as an adjunct therapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Pediatric neuroblastoma exhibits puzzling biological heterogeneity─some tumors regress spontaneously while high-risk cases resist intensive multimodal therapy─suggesting modifiable determinants of tumor fate beyond genes and proteins. Using a syngeneic MYCN-driven mouse model, we show that lipid composition acts as a switch, creating chemical environments that determine neuroblastoma progression implicating competing oxylipin signaling pathways. Ultrahigh dose oral arachidonic acid (ARA, ω6, 4.7 g/day human equivalent) dramatically accelerated tumorigenesis, producing 100% tumor incidence with solid non-necrotic masses 4-fold larger than controls. Conversely, docosahexaenoic acid (DHA, ω3, 24 g/day equivalent) profoundly suppressed tumor progression: half of the tumors regressed completely, while the remainder grew slowly, averaging 22% the size of controls and 6% the size of ARA tumors. Comprehensive oxylipin profiling via LC-MS/MS revealed divergent oxylipin profiles: ARA metabolism via cyclooxygenase, lipoxygenase, and cytochrome P450 pathways generated pro-tumorigenic eicosanoids (PGE2, TXB2, EETs) that drive angiogenesis, tumor cell proliferation, and invasion. In contrast, DHA competitively suppressed ARA-derived eicosanoid synthesis while enriching tissues with anti-inflammatory, pro-resolving mediators (17,18-EpETE, 18-HEPE, 14-HDHA) that inhibit pathological angiogenesis and tumor growth. Both treatments were well tolerated in our model at projected doses safe in adult humans for other indications. Because COX/LOX/CYP450-mediated oxylipin signaling operates across solid tumors, these findings support dietary highly unsaturated fatty acid composition as a candidate, modifiable determinant of cancer progression, suggesting ultrahigh dose omega-3 fatty acids as a low-toxicity adjunct to conventional therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.